Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.13, no.4, pp.330-334, 2008 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 13 Issue: 4
- Publication Date: 2008
- Doi Number: 10.1007/s10147-007-0757-8
- Journal Name: INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.330-334
- Istanbul University Affiliated: Yes
Abstract
Background. Pegylated liposomal doxorubicin (PLD) is the only nonplatinum agent to significantly improve survival in patients with platinum-sensitive recurrent ovarian cancer. The present study was designed to assess the efficacy and safety of PLD plus cisplatin combination therapy in these patients.